BioVie Past Earnings Performance
Past criteria checks 0/6
BioVie's earnings have been declining at an average annual rate of -19%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
-19.0%
Earnings growth rate
11.3%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -577.5% |
| Net Margin | n/a |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How BioVie makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -43 | 9 | 35 |
| 30 Sep 23 | 0 | -51 | 11 | 35 |
| 30 Jun 23 | 0 | -50 | 12 | 33 |
| 31 Mar 23 | 0 | -49 | 12 | 31 |
| 31 Dec 22 | 0 | -41 | 12 | 23 |
| 30 Sep 22 | 0 | -31 | 9 | 21 |
| 30 Jun 22 | 0 | -26 | 10 | 17 |
| 31 Mar 22 | 0 | -150 | 7 | 143 |
| 31 Dec 21 | 0 | -145 | 7 | 140 |
| 30 Sep 21 | 0 | -143 | 7 | 136 |
| 30 Jun 21 | 0 | -184 | 5 | 133 |
| 31 Mar 21 | 0 | -71 | 5 | 2 |
| 31 Dec 20 | 0 | -69 | 3 | 2 |
| 30 Sep 20 | 0 | -59 | 1 | 1 |
| 30 Jun 20 | 0 | -34 | 1 | 1 |
| 31 Mar 20 | 0 | -15 | 1 | 1 |
| 31 Dec 19 | 0 | -16 | 1 | 1 |
| 30 Sep 19 | 0 | -23 | 1 | 1 |
| 30 Jun 19 | 0 | -2 | 1 | 1 |
| 31 Mar 19 | 0 | -2 | 1 | 1 |
| 31 Dec 18 | 0 | -2 | 1 | 1 |
| 30 Sep 18 | 0 | -2 | 1 | 1 |
| 30 Jun 18 | 0 | -2 | 2 | 0 |
| 31 Mar 18 | 0 | -2 | 2 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
| 30 Sep 16 | 0 | -1 | 0 | 0 |
| 30 Jun 16 | 0 | 0 | 0 | 0 |
| 31 Mar 16 | 0 | 0 | 0 | 0 |
| 31 Dec 15 | 0 | 0 | 0 | 0 |
| 30 Sep 15 | 0 | 0 | 0 | 0 |
| 30 Jun 15 | 0 | 0 | 0 | 0 |
| 31 Mar 15 | 0 | 0 | 0 | 0 |
| 31 Dec 14 | 0 | 0 | 0 | 0 |
| 30 Sep 14 | 0 | 0 | 0 | 0 |
| 30 Jun 14 | 0 | 0 | 0 | 0 |
Quality Earnings: BIVI is currently unprofitable.
Growing Profit Margin: BIVI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIVI is unprofitable, and losses have increased over the past 5 years at a rate of 19% per year.
Accelerating Growth: Unable to compare BIVI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIVI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: BIVI has a negative Return on Equity (-577.54%), as it is currently unprofitable.